Addressing the Difficult AMD Cases
When it comes to AMD treatment, an open mind is essential.
Coding Q & A
Modifier 25 + Intravitreal Injections + NCCI Bundles
Combining Genetics With Disease Stage To Optimize AMD Management
Factoring genetic predisposition into risk assessment leads to improved detection of CNV and reduced monitoring burden.
Controversies in Care
Anti-VEGF Dosing Strategies for Macular Edema due to RVO
Lutein and Zeaxanthin In Early AMD
AREDS identified these carotenoids as relevant to early AMD, but what are the applications?
Management of Hazy View and Small Pupil During Vitreoretinal Surgery
Problems with visualization can add an additional challenge to retinal surgery.
Pharmacodynamics Of Visual Cycle Modulation In the Treatment of GA
Emerging data from clinical studies demonstrate the biological activity of emixustat in the retina.
RPS 2013: Viva Las Vegas
Presentations on ASCs and surgery for diabetic eye disease from the 2013 Retinal Physician Symposium
Subspecialty News
Self-injected DME drug; Ophthotech files stock offering; Eyedrop Will Be Studied for RVO; Regeneron DME trials; and more
By Jerry Helzner, contributing editor
Taking a Wider View in the Treatment of DME
Ultrawidefield fluorescein angiography will improve our ability to identify untreated peripheral pathology.
Update on the Use of Intraocular Steroids For Posterior-segment Diseases
More choices exist than ever before, but complications persist as well.
New Insights from ARVO
Exploring patient outcomes when switching anti-VEGF therapies.
Switching Anti-VEGF Therapies
Factors to consider when evaluating your AMD treatment plan